Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-172 in hyperphosphatemia patients on hemodialysis
NCT07285304Phase 3Recruiting
- Sponsor
- Taisho Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TS-172 in hyperphosphatemia, sponsored by Taisho Pharmaceutical. Started Dec 2025; status: recruiting.
02
Drugs
TS-172
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT07285304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285304.